Cross-reactivity observed with 1 or more available related molecules.< 50% cross-species reactivity observed with species tested.
No significant interference observed with available related molecules.
The Quantikine Human Amyloid beta (aa1-42) Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human Amyloid beta (aa1-42) in cell culture supernates, tissue lysates, and cerebrospinal fluid. It contains synthetic human Amyloid beta (aa1-42) and antibodies raised against the synthetic peptide. Results obtained for naturally occurring human Amyloid beta (aa1-42) showed linear curves that were parallel to the standard curves obtained using the kit standards. These results indicate that this kit can be used to determine relative mass values for natural human Amyloid beta (aa1-42).
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
The recovery of human Amyloid beta (aa1-42) spiked to levels throughout the range of the assay in various matrices was evaluated.
Average % Recovery
Cell Culture Media (n=4)
Cell Lysis Buffer (n=2)
Cerebrospinal Fluid (n=4)
To assess linearity of the assay, samples containing and/or spiked with high concentrations of human Amyloid beta (aa1-42) were diluted with Diluent RD2-7 to produce samples with values within the dynamic range of the assay.
Preparation and Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: Amyloid beta
Amyloid Precursor Protein (APP) is a type I transmembrane protein that is ubiquitously expressed on cell surfaces. It undergoes complex proteolytic processing and is cleaved by alpha-, beta-, and gamma-Secretases to generate soluble APP alpha, soluble APP beta, and Amyloid beta (A beta) fragments of several lengths. One of these fragments, A beta 42, generated by beta- and gamma-Secretase activities, has been implicated in Alzheimer's disease. Aberrantly high levels of this peptide form and accumulate in the brains of Alzheimer's disease patients to create the senile plaques characteristic of the disease.